drugset / Trial / NCT00371111

To Compare Therapeutic Effect of Intravitreal Bevacizumab and Triamcinolone in Resistant Uveitic Cystoid Macular Edema

NCT00371111

RandomizedParallel-groupSingle-blindTreatment

Summary

Cystoid macular edema (CME) is one of the common causes of vision loss in patients with UveitiS .Triamcinolone has been effectively used in reducing CME and improving the vision. Also there are some documents which recommend Bevacizumab(avastin) could reduce macular edema. This study compare intravitreous injection of triamcinolone and avastin in patients with resistant uveitic cystoid macular edema.

Timeline

Start
2006-08
Primary completion
2008-05
Completion
2008-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator Bevacizumab Monoclonal antibody 1.25 mg Intravitreal
Comparator Triamcinolone Other / unclassified 4 mg Intravitreal

Indications